RxSight (RXST) Free Cash Flow Growth (1y) (2021 - 2026)
RxSight (RXST) Free Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.65 Bn | 175.35 Bn | 6.27 Bn | -1.82% |
| 2 | Stryker | 128.95 Bn | 126.08 Bn | 3.81 Bn | 226.77% |
| 3 | Medtronic | 108.30 Bn | 99.08 Bn | 6.41 Bn | 0.77% |
| 4 | Boston Scientific | 68.31 Bn | 66.85 Bn | 3.61 Bn | -51.69% |
| 5 | Edwards Lifesciences | 48.19 Bn | 44.52 Bn | 1.29 Bn | -109.40% |
| 6 | Dexcom | 28.33 Bn | 27.21 Bn | 750.30 Mn | 363.84% |
| 7 | GE HealthCare Technologies | 28.02 Bn | 25.74 Bn | 1.98 Bn | -31.71% |
| 8 | Smith & Nephew | 26.97 Bn | 26.39 Bn | - | - |
| 9 | Koninklijke Philips | 24.06 Bn | 20.93 Bn | 2.07 Bn | 133.09% |
| 10 | RxSight | 230.08 Mn | -188.13 Mn | 23.50 Mn | -28.93% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.93% |
| Dec 31, 2025 | 72.55% |
| Sep 30, 2025 | 274.39% |
| Jun 30, 2025 | -13.23% |
| Mar 31, 2025 | 19.87% |
| Dec 31, 2024 | 48.37% |
| Sep 30, 2024 | 95.80% |
| Jun 30, 2024 | 27.88% |
| Mar 31, 2024 | 37.44% |
| Dec 31, 2023 | 18.40% |
| Sep 30, 2023 | 31.53% |
| Jun 30, 2023 | 51.62% |
| Mar 31, 2023 | -17.38% |
| Dec 31, 2022 | -41.22% |
| Sep 30, 2022 | -25.42% |
| Jun 30, 2022 | -24.23% |
| Mar 31, 2022 | -42.84% |
| Dec 31, 2021 | -36.99% |
| Sep 30, 2021 | -66.49% |